Reltecimod

• Description :

  Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs) [1][2].

• Product Name Alternative :

  AB-103

• UNSPSC :

  12352209

• Target :

  Bacterial; CD28

• Type :

  Peptides

• Related Pathways :

  Anti-infection; Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection; Inflammation/Immunology; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/reltecimod.html

• Purity :

  99.88

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](CC(O)=O)C(N[C@H](C)C(O)=O)=O)=O)NC([C@H](C)NC([C@H](C(C)C)NC([C@H](CC(C)C)NC([C@H](CCSC)NC([C@H]2N(CCC2)C([C@H](CO)NC([C@H](N)C)=O)=O)=O)=O)=O)=O)=O

• Molecular Formula :

  C46H72N10O15S

• Molecular Weight :

  1037.19

• References & Citations :

  [1]Shirvan, A., et al. Reltecimod. T-cell-specific surface glycoprotein CD28 (TP44) antagonist, CD28 homodimer interface mimetic peptide, Treatment of necrotizing soft-tissue infection. Drugs Fut 2018, 43 (4) : 243|[2]Edgar, R., Tarrio, M.L., Maislin, G. et al. Treatment with One Dose of Reltecimod is Superior to Two Doses in Mouse Models of Lethal Infection. Int J Pept Res Ther 26, 1669–1683 (2020) .

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category :

  Peptides

• Clinical Information :

  Phase 3

• CAS Number :

  [1447799-33-8]